ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

ARGX argenx SE

381.37
-5.63 (-1.45%)
Pre Market
Last Updated: 10:36:52
Delayed by 15 minutes
Name Symbol Market Type
argenx SE NASDAQ:ARGX NASDAQ Depository Receipt
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  -5.63 -1.45% 381.37 380.50 381.03 1,427 10:36:52

argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024

22/02/2024 6:00am

GlobeNewswire Inc.


argenx (NASDAQ:ARGX)
Historical Stock Chart


From Dec 2023 to Jun 2024

Click Here for more argenx Charts.

February 22, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, February 29, 2024 at 2:30 PM CET (8:30 AM ET) to discuss its full year 2023 financial results and provide a fourth quarter business update.

A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation.

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker in the U.S., Japan, Israel, the EU, the UK, Canada and China. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Twitter, and Instagram.

For further information, please contact:

Media:

Ben PetokBPetok@argenx.com

Investors:

Alexandra Roy (US)aroy@argenx.com

Lynn Elton (EU)lelton@argenx.com

1 Year argenx Chart

1 Year argenx Chart

1 Month argenx Chart

1 Month argenx Chart

Your Recent History

Delayed Upgrade Clock